Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease, A Pilot Trial for Safety and Feasibility

NCT05870007 is registered in ClinicalTrials.gov with Taipei Medical University Shuang Ho Hospital as lead sponsor.

NCT NCT05870007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05870007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease, A Pilot Trial for Safety and Feasibility
Lead sponsor
Taipei Medical University Shuang Ho Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
May 31, 2023
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease, chronic kidney diseases